How life sciences manufacturing must adapt following Covid-19 – as published in European Pharmaceutical Manufacturing
Posted on June 23, 2020 by Helena Graham
The effect of the Covid-19 pandemic on the life sciences industry has been wide-reaching and dramatic – regional lockdowns, social distancing requirements and the associated supply chain disruptions, has meant rapid and sudden challenges to life sciences manufacturing.
This has resulted in changes from new on-site protocols to huge uptakes in remote production support, coinciding with greater emphasis on the digitisation of production processes. While most organisation were gradually working towards these, the pandemic imposed rapid, indelible changes on the industry.
In an article written for European Pharmaceutical Manufacturer, Pari Sanghavi, senior director, life sciences supply chain and manufacturing at Cognizant and Jim Lehane, global leader business development at Zenith Technologies discussed how manufacturing must adapt following Covid-19.
This article covers the increase in remote production support, remote/distributed acceptance testing, the revisions to on-site protocols and work layouts as well as how manufacturers are reconfiguring their supply chains to focus on resilience rather than efficiency, the full article is available here.
Zenith Technologies, a Cognizant Company, can help companies incorporate new technologies and work practices into their manufacturing plans, allowing them to run at full capacity while protecting their workforce and operating efficiently.
Find out more here.